San Francisco Monthly STD Report

Table 1. STDs among residents, March, 2021. Female syphilis cases include patients assigned as female at birth.

	2021 20			
	month	YTD	month	YTD
Gonorrhea	348	903	368	1,375
Male rectal gonorrhea	122	299	119	397
Chlamydia	460	1,312	485	2,105
Male rectal chlamydia	130	361	135	600
Syphilis (adult total)	184	514	119	439
Primary & secondary	34	112	38	127
Early latent	77	218	57	224
Unknown latent	41	89	10	33
Late latent	32	95	14	55
Neurosyphilis	4	9	2	4
Congenital syphilis	0	1	0	0
Female syphilis	19	44	13	44





Table 2. Selected STD cases and rates for San Francisco by age and race/ethnicity, 2021 through March only. Rates equal cases per 100,000 residents per year based on 2010 US Census Data.


	(All races)		Asian/PI		African American		Hispanic		White	
	cases	rate	cases	rate	cases	rate	cases	rate	cases	rate
All ages										
Chlamydia	1,312	651.7	163	245.4	166	1,419.4	229	752.2	322	381.7
Gonorrhea	903	448.6	88	132.5	156	1,333.9	187	614.3	287	340.2
Early syphilis	330	163.9	48	72.3	33	282.2	76	249.6	133	157.7
Under 20 yrs										
Chlamydia	116	834.6	9	162.6	32	2,721.7	22	695.5	7	228.4
Gonorrhea	21	151.1	0	0.0	9	765.5	7	221.3	0	0.0
Early syphilis	1	7.2	0	0.0	0	0.0	1	31.6	0	0.0


Table 3. HIV testing among City Clinic patients, March, 2021.

	2021			
	month	YTD	month	YTD
Tests	226	584	214	996
Antibody positive	3	10	5	11
Acute HIV infection	1	1	0	0

Note: All statistics are provisional until the annual report is released for the year. Morbidity is based on date of diagnosis. Totals for past months may change due to delays in reporting from labs and providers.







PrEP now generic, as cheap as \$1/day even with full cash pay!

As of April 1, 2021, multiple generics for emtricitabine/tenofovir DF 200/300mg (TDF/FTC, brand-name Truvada) have entered the market and driven costs down tremendously. Therefore, **even full cash pay should not cost more than \$40/month** in SF. Prices are not yet consistent across all pharmacies, and some pharmacies may continue to quote prices as high as >\$1,000+. Most should not need to pay cash, but for those who do, a solid plan is to prescribe to a pharmacy that you know consistently stocks a low-price generic. Plan B: check <u>GoodRx.com</u>.

A few other details:

- Most private insurance plans in CA, including Kaiser and all Covered CA plans, now cover generic TDF/FTC for PrEP with \$0 cost-sharing by the
 patient. This is because PrEP is now a USPSTF grade "A"-recommended preventive service.
- Generic TDF/FTC for PrEP should not be subject to a prior authorization by almost any CA-based insurance plan.
- Pharmacies are proactive in switching patients to generic, and most private plans now require it. There is no manufacturer coupon for the generics, so if still unaffordable, or if a patient needs financial assistance with co-payments for visits or labs, refer patients who earn <500% of FPL* to <u>PrEP-AP</u>.
- Uninsured patients using the <u>Gilead Patient Assistance Program</u> or the federal <u>Ready, Set, PrEP program</u> should be prescribed brand-name Truvada with "Do not substitute" on the Rx for coverage compatibility.

For more on policy developments related to PrEP access, please review <u>this brief</u>. And finally, thank you for prescribing PrEP! **If you would like help from SFDPH with how to prescribe PrEP or get OOP costs covered, please contact the City Clinic Biomedical Prevention Coordinator at montica.levy@sfdph.org.**

*500% of FPL is \$64,400 in annual income, as of April 30, 2021

Provider STD Reporting: 415-487-5555, 415-431-4628 (fax)